anaemia. Cases were also excluded if they had lived abroad for 6 months or more in the year prior to diagnosis. Following consent from the treating consultant, eligible patients were asked to participate in the study. Cases were usually contacted within 2 weeks of diagnosis or during the first remission (between 4 and 6 weeks after diagnosis). If the patient died before an interview was arranged, their partner or a closerelative was approached, with the permission of the case's treating consultant or general practitioner (GP), between 3 months and a year after death to act as a surrogate. Interviews were not undertaken with any patient who had insufficient command of English, was unable to communicate, or had severe mental disturbance where no suitable surrogate was available.
Two controls per case, individually matched to the case on sex, year of birth, ethnic origin and residence at diagnosis, were randomly selected from general practice lists; the majority being selected from the general practice where the case was registered. If the GP of the case refused, an adjacent general practice was approached. In Somerset, ethical committee permission for control selection from general practice lists was not granted, and controls were randomly selected by the Family Health Services Authority. Following consent from their GP, potential controls were sent a letter asking them to participate. If no reply was received within 2 weeks, an attempt was made to contact them by telephone, and if no reply was received after a month, another control was approached.
A total of 1066 acute leukaemia patients were identified. Interviews were obtained for 838 (79%) cases; 731 (87%) being with the case and 107 (13%) being with a surrogate. Permission to interview was refused by 40 (4%) consultants, 18 (2%) patients and 21 (2%) surrogates. A further 149 (14%) cases were not interviewed, either because a suitable surrogate could not be found, the patient could not be traced, or the subject was interviewed for another study. For the 838 interviewed cases, 3100 controls were asked to participate. Of the controls who were contacted successfully, 1658 (66%) agreed to participate and 854 (34%) refused. It is possible that the majority of the 588 potential controls who could not be contacted would have moved from the address supplied by All participating subjects were asked to complete a preinterview form, containing details of residential, occupational and medical history. Subjects were subsequently interviewed face-toface by trained personnel using a highly structured questionnaire. Topics covered included residential history, previous occupations and their exposures, medical history and familial cancer as well as smoking history. Exposure to tobacco was defined as the subject having smoked at least once a day for at least 6 months. Every change in habit, such as the type of tobacco smoked, and the number of cigarettes smoked per day, was recorded with the corresponding start and stop dates. A 2-year latent interval prior to diagnosis is assumed, based on the minimum induction period between initial exposure and the onset of leukaemia observed in cohorts exposed to known leukaemogens (Smith and Doll, 1982; Curtis et al, 1984; Aksoy, 1985; Rinsky et al, 1987) .
A deprivation indicator was created using the address at diagnosis. For each address, the postcode was validated against the Post Office Postcode Address File using QuickAddress TM (v2.0) and matched to a 1991 census small area, or 'enumeration district', via the PC2ED program available from Manchester Computing Service (MIDAS). Townsend scores were computed for each enumeration district in England and Wales using data from the 1991 census (Townsend et al, 1988) . Categorization of the resulting continuous variable provided a coding scheme for the enumeration districts of the addresses at diagnoses.
Odds ratios (OR) and 95% confidence intervals (CI) for matched analyses were calculated using conditional logistic regression (Breslow and Day, 1980) . Tests for trend were conducted using the likelihood-ratio test and the lowest exposure category was defined as the reference group. All analyses were performed using STATA (Stata Corporation, 1997) .
RESULTS
Among white interviewed cases, 695 (86%) were diagnosed with acute myeloid leukaemia (AML), 100 (12%) with acute lymphoblastic leukaemia (ALL) and 12 (1%) had unspecified acute leukaemia (Table 1) . A slightly higher proportion of cases than controls were single and had left school before the age of 17 years. Although these differences were not statistically significant, interviewed cases were more likely to live in deprived areas than their corresponding controls (χ 2 = 13.67, P = 0.03). Consequently, deprivation was adjusted for in the subsequent analyses. Table 2 shows the number of cases and controls by reported smoking status 2 years before diagnosis. For all acute leukaemia combined, 505 (63%) cases and 943 (59%) controls reported that they had regularly smoked tobacco (OR = 1.2, 95% CI 1.0-1.4). Compared with non-smokers, the effect was stronger in current smokers (OR = 1.4, 95% CI 1.1-1.7) than in ex-smokers (OR = 1.0, 95% CI 0.8-1.2). No increased risk was evident among those who smoked for fewer than 10 years (OR = 0.9, 95% CI 0.7-1.2). The odds ratio for those who had smoked for 10-19 years was 1.3 (95% CI 1.0-1.8), with similar risks among those who smoked for 20-29 years, 30-39 years, or 40 or more years, and so no significant linear dose-response relationship was evident.
Although the risk reduced rapidly as the number of years stopped smoking increased, there was no significant linear trend (χ 2 = 0.54, P = 0.76). Further, among smokers, there was no evidence of a dose-response relationship with the number of cigarettes smoked per day at 2 years prior to diagnosis: compared with those who smoked fewer than 15 cigarettes a day, the odds ratios for those smoking 15-24, and 25 or more cigarettes were 1.3 (95% CI 0.7-2.5) and 1.0 (95% CI 0.5-2.1) respectively. The numbers of subjects smoking other types of tobacco were small, but as far as we could tell, the risks were no different to that for cigarette smokers (data not shown).
The majority of cases were diagnosed with AML and the odds ratios for this cell type are generally equivalent to those for all acute leukaemia combined. Although none of the odds ratios for ALL were significantly raised, the point estimates are similar to those for AML.
DISCUSSION
The main finding is an association between tobacco use and acute leukaemia, which appears to be present for both AML and ALL. The data suggest that the risk is greatest amongst subjects who have smoked for at least 10 years. Further, the risk is elevated among current smokers, and declines to the risk of a non-smoker soon after cessation of smoking. However, no significant dose-response trends were observed, either with number of years smoked or with number of cigarettes smoked per day. (17) 331 (21) 2 141 (17) 290 (18) 3 137 (17) 282 (18) 4 114 (14) 224 (14) 5 111 (14) 197 (12) 6 90 (11) 162 (10) Deprivation coded using categories of the Townsend scores for England and Wales; cases are more likely to live in deprived areas than their matched controls (Pearson's χ 2 = 13.67, P = 0.03).
While published evidence for leukaemia and self-reported tobacco use is inconclusive (Kinlen and Rogot, 1988; Brownson, 1989; McLaughlin, 1989; Garfinkel and Boffetta, 1990; Mills et al, 1990; Spitz et al, 1990; Brownson et al, 1991; Linet et al, 1991; Brown et al, 1992a; Sandler et al, 1993; McLaughlin et al, 1995; Engeland et al, 1996; Adami et al, 1998) , studies tend to suggest a weak association for AML (Severson, 1987; Brownson, 1989; Severson et al, 1990; Brownson et al, 1991; Brown et al, 1992a; Friedman, 1993; Sandler et al, 1993; Mele et al, 1994; Pasqualetti et al, 1997) , with only a few studies not reporting an increased risk (Cartwright et al, 1988; Kabat et al, 1988; Spitz et al, 1990; Crane et al, 1992) . Indeed, pooling the odds ratios from all case-control studies published to date suggests that smoking could increase the risk of AML by about 20% (Table 3) . This increase is similar to those reported in previous meta-analyses (Brownson et al, 1993; Siegel, 1993) . However, these estimates should be treated cautiously since there is strong evidence of heterogeneity between studies, possibly arising from heterogeneous populations and/ or different study designs (Hardy and Thompson, 1998) . Interestingly, the pooled risk estimate changes little when only population-based case-control studies (Severson, 1987; Severson et al, 1990; Brown et al, 1992a; Sandler et al, 1993 ; and the present study) are considered, despite there being less evidence of heterogeneity (χ 2 = 4.99, P = 0.29). Published evidence does not favour an association between ALL and smoking (Kabat et al, 1988; Brown et al, 1992a; Sandler et al, 1993; Mele et al, 1994; Pasqualetti et al, 1997) , possibly as many studies lack power to detect a significant risk due to small numbers of cases. Indeed, only one case-control study of comparable size to the present has been published, with a risk estimate and 95% confidence interval (OR = 1.3, 95% CI 0.8-2.0) similar to the result reported here (Sandler et al, 1993) . This suggests that the increased risk from smoking for ALL may be similar to that for AML. Dose-response relationships for AML and ALL have previously been evaluated using the number of cigarettes consumed per day (Kabat et al, 1988; Brownson, 1989; Severson et al, 1990; Brownson et al, 1991; Brown et al, 1992a; Crane et al, 1992; Friedman, 1993) , the number of years smoked (Severson, 1987; Severson et al, 1990; Brown et al, 1992a; Friedman, 1993) , or pack-years (Severson et al, 1990; Crane et al, 1992; Sandler et al, 1993; Mele et al, 1994) . While the majority of studies found no evidence of a trend in risk with number of cigarettes smoked per day (Kabat et al, 1988; Brownson, 1989; Brownson et al, 1991; Brown et al, 1992a; Crane et al, 1992) , significant increasing trends with increasing number of years smoked were found in two studies (Severson, 1987; Severson et al, 1990 ). More consistent with this study were the relatively constant odds ratios for AML with years smoked observed in another study (Brown et al, 1992a) . Although significant increasing trends of pack-years were reported in previous studies (Severson et al, 1990; Sandler et al, 1993; Mele et al, 1994) , it was felt that for the current analysis pack-years were inappropriate as not only does this variable not account for time with respect to diagnosis, it also accrues errors resulting from recall bias. Moreover, the presented results suggest that those who stopped smoking over 20 years before diagnosis were not at risk and so an analysis of lifetime exposure expressed in pack-years is probably unsuitable.
Evidence that current smokers have increased risk of acute leukaemia has been found in three other case-control studies (Severson et al, 1990; Brown et al, 1992a; Mele et al, 1994) . Tests for trend in number of years since stopped uses 21+ years as baseline; χ 2 = 0.54 (P = 0.76) for acute leukaemia, χ 2 = 1.64 (P = 0.44) for AML, and χ 2 = 0.79 (P = 0.68) for ALL.
Unlike our report, however, these studies also found associations for ex-smokers. This difference probably reflects the fact that, like others (Smith and Doll, 1982; Curtis et al, 1984; Aksoy, 1985; Rinsky et al, 1987) , we lagged the exposure data 2 years before diagnosis, partly to account for latency and partly because of concerns about changing habits as the illness onsets. Hence, individuals who gave up smoking within the 2 years leading up to diagnosis would have been classified as a current smoker in our study and as an ex-smoker (even if given up in the week before diagnosis) in other studies (Severson et al, 1990; Brown et al, 1992a; Mele et al, 1994) . One of these studies also suggested decreasing risks with increasing number of years since quit smoking, but this result was based on small numbers (Severson et al, 1990) . The level of completeness of cases in this study is known to be high as all cases are registered on the Leukaemia Research Fund's Data Collection Study , which is estimated to be 98.5% complete for AML and ALL . Of more concern is the high number of non-participating subjects. Cases and controls who refused to participate tended to live in more deprived areas than interviewed subjects, and so were more likely to smoke (Hay and Foster, 1984; Bennett et al, 1996) . As the refusal rate for controls is considerably higher than for cases, the resulting risk estimates may be overestimated. However, adjustment for deprivation did not alter the association of tobacco exposure and acute leukaemia (unadjusted OR = 1.2, 95% CI 1.0-1.4).
A major problem with case-control studies of the type reported here is the retrospective collection of self-reported exposure information. As smoking is not a widely accepted cause of leukaemia, exaggeration of exposure by cases seems improbable. While under-reporting by controls cannot be ruled out, the smoking habits reported appear consistent with a sample of the general population (Bennett et al, 1996) . For diseases with poor prognosis, a further problem surrounds the issue of surrogate interviews. If they are not attempted, then the completeness of the study is compromised. On the other hand, surrogate information about factors such as smoking may be poor. Fortunately, the quick referral of cases into our study ensured that only a small proportion of interviews (13%) were with surrogates. Removing the few proxy interviews made little difference to the risk estimate for ever compared with never smoked (OR = 1.2, 95% CI 1.0-1.5 based on 702 cases and 1385 controls), and the odds ratios for the number of years smoked and the number of years since quit were similarly unaffected (data not shown).
As the effect of smoking on the risk of acute leukaemia appears to be comparatively small, confounding by other factors may be important. Evidence for other risk factors that could be related to smoking is, however, sparse and contradictory. Nonetheless, it is unfortunate that information on habits such as alcohol consumption (Williams and Horm, 1977; Jensen, 1979; Blackwelder et al, 1980; Hinds et al, 1980; Schmidt and Popham, 1981; Carstensen et al, 1990; Brown et al, 1992b) and variations in diet (Hursting et al, 1990; Kwiatkowski, 1993) were not collected in this study.
While our increased risk could be confounded by other risk factors, a causal relationship between tobacco smoke and acute leukaemia seems plausible. Known or suspected leukaemogens, for example benzene, radioactive lead and polonium, nitrosamines and urethanes, are present in tobacco smoke. The levels of such chemicals in one packet of 20 cigarettes are considerably less than in some work environments, so it seems unlikely that any one chemical constituent of tobacco smoke could solely cause the increased risk of acute leukaemia. Although the biological mechanisms are unknown, tobacco smoke has been associated with chromosomal defects in the peripheral blood (Perera et al, 1987) , immunological changes such as increases in the leucocyte count (Petitti and Kipp, 1986) and decreases in natural killer cell activity (Hersey et al, 1983) ; all factors that are linked to leukaemia (Heath, 1982) . In addition, long-term use exacerbates such changes (Ghosh and Ghosh, 1987; Petitti and Kipp, 1986) while quitting results in a subsequent decline in the leucocyte count (Petitti and Kipp, 1986) , an increase in natural killer cell activity (Hersey et al, 1983 ) and a decrease in DNA damage (Frenzilli et al, 1997) . Hence, our observed increased risk of acute leukaemia with 10 or more years of tobacco use and a decline in the odds ratios with increasing number of years since stopping seems reasonable.
In conclusion, AML was found to be associated with smoking, and the risk was greatest for those who smoked for 10 or more years and who were still smoking at 2 years before diagnosis. It appears that the risk of ALL from tobacco was no different to the risk of AML, but small numbers have hampered our investigation. Although no trend was observed for number of years smoked or number of cigarettes per day, there was evidence that the risk of acute leukaemia decreases on cessation of smoking.
